Published in Virology on February 15, 2000
The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol (2003) 1.91
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A (2006) 1.57
Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A (2005) 1.50
Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy. Am J Pathol (2014) 1.49
The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res (2007) 1.39
The papillomavirus E7 proteins. Virology (2013) 1.28
Papillomavirus E6 oncoproteins. Virology (2013) 1.21
HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology (2008) 1.16
A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J Virol (2002) 1.15
Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res (2007) 1.13
Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology (2008) 1.11
Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene (2008) 1.10
Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells. J Virol (2003) 1.08
p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res (2008) 1.06
Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol (2012) 1.05
Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int J Biol Sci (2010) 1.05
A role for HPV16 E5 in cervical carcinogenesis. Cancer Res (2010) 1.03
HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP. Oncogene (2006) 1.00
Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology (2010) 1.00
Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol (2005) 0.99
Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res (2007) 0.98
Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys (2014) 0.97
A mouse model for human anal cancer. Cancer Prev Res (Phila) (2010) 0.96
E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures. J Virol (2009) 0.96
PATJ, a tight junction-associated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6. J Virol (2007) 0.95
Nuclear entry of high-risk human papillomavirus type 16 E6 oncoprotein occurs via several pathways. J Virol (2003) 0.93
Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) and LMP2A function cooperatively to promote carcinoma development in a mouse carcinogenesis model. J Virol (2012) 0.93
Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev (2014) 0.93
The invasive capacity of HPV transformed cells requires the hDlg-dependent enhancement of SGEF/RhoG activity. PLoS Pathog (2012) 0.92
Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PLoS One (2013) 0.90
E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res (2010) 0.90
How does tobacco smoke contribute to cervical carcinogenesis? J Virol (2008) 0.90
Absolute quantitative real-time polymerase chain reaction for the measurement of human papillomavirus E7 mRNA in cervical cytobrush specimens. Infect Agent Cancer (2007) 0.90
p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol (2011) 0.89
Tumorigenic activity of merkel cell polyomavirus T antigens expressed in the stratified epithelium of mice. Cancer Res (2015) 0.89
Dominant role of HPV16 E7 in anal carcinogenesis. Virology (2011) 0.88
The E6 oncoprotein from HPV16 enhances the canonical Wnt/β-catenin pathway in skin epidermis in vivo. Mol Cancer Res (2011) 0.87
Progressive transformation of immortalized esophageal epithelial cells. World J Gastroenterol (2002) 0.84
Gene expression profile of cervical and skin tissues from human papillomavirus type 16 E6 transgenic mice. BMC Cancer (2008) 0.82
Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain. PLoS One (2013) 0.82
Increased incidence of squamous cell carcinomas in Mastomys natalensis papillomavirus E6 transgenic mice during two-stage skin carcinogenesis. J Virol (2004) 0.82
HUMAN PAPILLOMAVIRUS ASSOCIATION WITH HEAD AND NECK CANCERS: UNDERSTANDING VIRUS BIOLOGY AND USING IT IN THE DEVELOPMENT OF CANCER DIAGNOSTICS. Expert Opin Med Diagn (2008) 0.80
Physical labeling of papillomavirus-infected, immortal, and cancerous cervical epithelial cells reveal surface changes at immortal stage. Cell Biochem Biophys (2012) 0.80
Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma. Onco Targets Ther (2016) 0.79
Ultrabright fluorescent mesoporous silica nanoparticles for prescreening of cervical cancer. Nanomedicine (2013) 0.78
A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. J Transl Med (2015) 0.77
A Drosophila Model of HPV E6-Induced Malignancy Reveals Essential Roles for Magi and the Insulin Receptor. PLoS Pathog (2016) 0.77
HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy. BMC Cancer (2015) 0.76
Modulation of therapeutic sensitivity by human papillomavirus. Radiother Oncol (2015) 0.76
HPV Associated Head and Neck Cancer. Cancers (Basel) (2016) 0.76
Dysregulation of Autophagy Contributes to Anal Carcinogenesis. PLoS One (2016) 0.75
Model-Based Tumor Growth Dynamics and Therapy Response in a Mouse Model of De Novo Carcinogenesis. PLoS One (2015) 0.75
Construction and detection of the tissue-specific pINV-HPV16 E6/7 vector. Oncol Lett (2014) 0.75
Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo (2014) 0.75
Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med (1999) 5.82
A transcriptional repressor encoded by BPV-1 shares a common carboxy-terminal domain with the E2 transactivator. Cell (1987) 5.75
Carcinogenesis by chemicals: an overview--G. H. A. Clowes memorial lecture. Cancer Res (1970) 4.83
Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation (1998) 3.70
Bovine papillomavirus transcriptional regulation: localization of the E2-responsive elements of the long control region. J Virol (1987) 3.66
Carcinogens as frameshift mutagens: metabolites and derivatives of 2-acetylaminofluorene and other aromatic amine carcinogens. Proc Natl Acad Sci U S A (1972) 3.61
Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol (1995) 3.57
Mitochondrial DNA analysis in Tibet: implications for the origin of the Tibetan population and its adaptation to high altitude. Am J Phys Anthropol (1994) 3.40
Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A (1995) 2.79
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
8-(N-2-fluorenylacetamido)guanosine, an arylamidation reaction product of guanosine and the carcinogen N-acetoxy-N-2-fluorenylacetamide in neutral solution. Biochemistry (1967) 2.69
Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer (1981) 2.65
Tn5/IS50 target recognition. Proc Natl Acad Sci U S A (1998) 2.47
Two different molecular organizations account for the single alpha-globin gene of the alpha-thalassemia-2 genotype. J Clin Invest (1980) 2.38
C'2ad, an inactive derivative of C'2 released during decay of EAC'4,2a. Immunochemistry (1966) 2.37
The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex. Genes Dev (1991) 2.24
Principal glycopeptide of the tetrodotoxin/saxitoxin binding protein from Electrophorus electricus: isolation and partial chemical and physical characterization. Biochemistry (1983) 2.22
Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem (1989) 2.22
Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res (1972) 2.18
Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol (1996) 2.12
The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol (2000) 2.05
The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol (1999) 2.01
Mechanisms of chemical carcinogenesis: nature of proximate carcinogens and interactions with macromolecules. Pharmacol Rev (1966) 1.98
Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology (1999) 1.96
Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J Virol (1997) 1.92
2,3-Dihydro-2-(guan-7-yl)-3-hydroxy-aflatoxin B1, a major acid hydrolysis product of aflatoxin B1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res (1977) 1.88
Microscopic pulmonary tumor emboli associated with dyspnea. Cancer (1975) 1.86
Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet (1997) 1.77
Aflatoxin B1-2,3-oxide as a probable intermediate in the covalent binding of aflatoxins B1 and B2 to rat liver DNA and ribosomal RNA in vivo. Cancer Res (1977) 1.67
The Clock Test: a sensitive measure to differentiate normal elderly from those with Alzheimer disease. J Am Geriatr Soc (1992) 1.64
Polyimides as biomaterials: preliminary biocompatibility testing. Biomaterials (1993) 1.60
Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol (1997) 1.57
Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation. J Virol (1993) 1.54
Three-dimensional cinematography with control object of unknown shape. J Biomech (1982) 1.52
A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest (1998) 1.51
Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res (1977) 1.50
Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci U S A (1993) 1.48
Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A (1997) 1.48
Bovine papillomavirus type 1 E2 transcriptional regulators directly bind two cellular transcription factors, TFIID and TFIIB. J Virol (1995) 1.48
Nucleic acid guanine: reaction with the carcinogen N-acetoxy-2-acetylaminofluorene. Science (1966) 1.47
Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B6C3 F1 mouse. Proc Natl Acad Sci U S A (1986) 1.47
Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res (1996) 1.47
Nonenzymatic glycosylation of erythrocyte membrane proteins. Relevance to diabetes. J Clin Invest (1980) 1.47
Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res (1983) 1.45
Limitation of myocardial infarct size after primary angioplasty: is a higher patency the only mechanism? Am Heart J (1999) 1.43
High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol (1998) 1.42
Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A (1998) 1.41
Contraction of filaments of Escherichia coli after disruption of cell membrane by detergent. J Bacteriol (1987) 1.40
Transfusion of blood and blood products. Prof Nurse (1989) 1.39
Aflatoxin B1-2,3-oxide: evidence for its formation in rat liver in vivo and by human liver microsomes in vitro. Biochem Biophys Res Commun (1974) 1.31
Mechanisms of chemical carcinogenesis. Cancer (1981) 1.30
Interaction of the papillomavirus transcription/replication factor, E2, and the viral capsid protein, L2. Virology (2000) 1.26
N-hydroxy-2-acetylaminofluorene sulfotransferase: its probable role in carcinogenesis and in protein-(methion-S-yl) binding in rat liver. Cancer Res (1970) 1.26
Anatomy and significance of fixation of the lumbosacral nerve roots in sciatica. Spine (Phila Pa 1976) (1983) 1.24
Estimation of apurinic/apyrimidinic sites and phosphotriesters in deoxyribonucleic acid treated with electrophilic carcinogens and mutagens. Biochemistry (1980) 1.24
The metabolic activation of carcinogenic aromatic amines and amides. Prog Exp Tumor Res (1969) 1.23
Inhibition of guinea pig C'2 by rabbit antibody. Quantitative measurement of inhibition, discrimination between immune inhibition and complement fixation, specificity of inhibition and demonstration of uptake of C'2 by EAC'1a,4. Immunochemistry (1965) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
Secondary prevention with folic acid: results of the Goes extension study. Heart (2005) 1.22
A specific method for purification of the second component of guinea pig complement and a chemical evaluation of the one-hit theory. J Immunol (1970) 1.21
Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol (1994) 1.20
Epidemiology of pulmonary lesions in nontextile and cotton textile workers: a retrospective autopsy analysis. Arch Environ Health (1980) 1.18
1,N6-ethenoadenosine formation, mutagenicity and murine tumor induction as indicators of the generation of an electrophilic epoxide metabolite of the closely related carcinogens ethyl carbamate (urethane) and vinyl carbamate. Carcinogenesis (1990) 1.17
Coronavirus isolation from nasal swab samples in cattle with signs of respiratory tract disease after shipping. J Am Vet Med Assoc (1996) 1.16
Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology (1997) 1.16
Species variations in the N- and ring-hydroxylation of 2-acetylaminofluorene and effects of 3-methylcholanthrene pretreatment. Proc Soc Exp Biol Med (1967) 1.15
Fetal alcohol exposure and temporal vulnerability: regional differences in cell loss as a function of the timing of binge-like alcohol exposure during brain development. Alcohol Clin Exp Res (1999) 1.14
Covalent intercalative binding to DNA in relation to the mutagenicity of hydrocarbon epoxides and N-acetoxy-2-acetylaminofluorene. Cancer Res (1978) 1.14
Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol (2001) 1.14
Repolarization-induced reactivation of contracture tension in frog skeletal muscle. Can J Physiol Pharmacol (1973) 1.14
Mutations and decreases in density of transforming DNA produced by derivatives of the carcinogens 2-acetyl-aminofluorene and N-methyl-4-aminoazobenzene. Mol Pharmacol (1968) 1.13
Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice. J Virol (1997) 1.13
Analysis and measurement of neck loads. J Orthop Res (1988) 1.12
Thoracic surgical problems associated with rheumatoid arthritis. J Thorac Cardiovasc Surg (1975) 1.12
The reactivity and carcinogenicity of aflatoxin B1-2,3-dichloride, a model for the putative 2,3-oxide metabolite of aflatoxin B1. Cancer Res (1975) 1.11
2,3-Dihydro-2,3-dihydroxy-aflatoxin B1: an acid hydrolysis product of an RNA-aflatoxin B1 adduct formed by hamster and rat liver microsomes in vitro. Biochem Biophys Res Commun (1973) 1.11
Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif (1995) 1.11
Load-displacement behavior of sacroiliac joints. J Orthop Res (1987) 1.10
The biological responses of axotomized adult motoneurons to brain-derived neurotrophic factor. J Neurosci (1994) 1.09
Isolation and characterization of a bacteriophage of Arthrobacter globiformis. J Virol (1973) 1.09
The '4-poster' passive topical treatment device to apply acaricide for controlling ticks (Acari: Ixodidae) feeding on white-tailed deer. J Med Entomol (2000) 1.08
Bovine papillomavirus type 1 E1 and simian virus 40 large T antigen share regions of sequence similarity required for multiple functions. J Virol (1997) 1.08
3-methylmercapto-N-methyl-4-aminoazobenzene: an alkaline-degradation product of a labile protein-bound dye in the livers of rats fed N,N-dimethyl-4-aminoazobenzene. Biochem Biophys Res Commun (1965) 1.07
Low carcinogenicity of the K-region epoxides of 7-methylbenz(a)-anthracene and benz(a)anthracene in the mouse and rat. Proc Soc Exp Biol Med (1967) 1.07
The primary structure of coho salmon growth hormone and its cDNA. Gen Comp Endocrinol (1987) 1.07
Non-arene oxide aromatic ring hydroxylation of 2,2',5,5'-tetrachlorobiphenyl as the major metabolic pathway catalyzed by phenobarbital-induced rat liver microsomes. J Biol Chem (1983) 1.07
Guanyl O6-arylamination and O6-arylation of DNA by the carcinogen N-hydroxy-1-naphthylamine. Cancer Res (1978) 1.07
Load-displacement properties of lower cervical spine motion segments. J Biomech (1988) 1.05
Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1'-sulfoöxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1'-hydroxysafrole in mouse liver. Cancer Res (1983) 1.05
The birth of retropubic prostatectomy--Millin. J R Soc Med (1989) 1.04
Differences in the ability of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 tax to inhibit p53 function. J Virol (2000) 1.04
Carcinogens occurring naturally in foods. Fed Proc (1976) 1.04
Electron microscopic visualization of the tetrodotoxin-binding protein from Electrophorus electricus. Proc Natl Acad Sci U S A (1982) 1.03
The effect of insulin-like growth factor I on postburn hypermetabolism. Surgery (1990) 1.02
Sulfotransferase activation of N-hydroxy-2-acetylaminofluorene in rodent livers susceptible and resistant to this carcinogen. Proc Soc Exp Biol Med (1968) 1.02